Midday Movers & Shakers: Biotech Buzz, Treasury Vision & Green Tech Breakouts

September 10, 2025

DENVER, Colo., Sep 10, 2025 (247marketnews.com)- Lixte Biotechnology (NASDAQ:LIXT) is attracting investor attention as bullish sentiment builds around its lead compound LB‑100, a first-in-class Protein Phosphatase 2A (PP2A) inhibitor dubbed a “cancer power-up” for its ability to enhance chemotherapy and immunotherapy. With fewer than 5 million shares outstanding, LIXT’s low float and high short interest (60% borrow fee, 400% maintenance requirement) make it a prime candidate for a short squeeze, potentially pushing it toward new 52-week highs. Currently in clinical trials for ovarian clear-cell carcinoma with GlaxoSmithKline (NYSE:GSK), LB‑100 is poised for a breakout, potentially spearheading a move to 52-week highs. Stay alert for upcoming oncology conferences or favorable Phase 2 trial data that could fuel extended gains.

Cuprina Holdings (NASDAQ:CUPR) secured exclusive licensing rights to Southeast Asia’s first medical waste recycling technology under the UNIDO/GEF framework. This steam-based sterilization process transforms plastic medical waste into high-value resins, a sustainable alternative to incineration. Starting with Singapore and potentially expanding into 10 regional countries, the move positions Cuprina as a leader in rising environmental standards and transformative waste management infrastructure.

With Singapore’s biohazardous waste rising from 4,400 tons in 2016 to 5,700 tons in 2020 (MOH Singapore), and the Asia-Pacific medical waste management market projected to grow at a 10.2% CAGR to $15.8 billion by 2030 (Grand View Research), CUPR is well-positioned to capitalize on tightening environmental standards.

Wearable Devices (NASDAQ:WLDS): Up 4.1%, driven by growing interest in its neural interface wearables. The global wearable technology market, valued at $61.3 billion in 2024, is projected to reach $186.1 billion by 2030 (CAGR 20.2%, Statista), fueling WLDS’s momentum.

Asset Entities (NASDAQ:ASST) recent digital marketing partnerships keep it on watch. The global digital marketing market is expected to hit $1.5 trillion by 2030 (CAGR 17.6%, Grand View Research).

Travere Therapeutics (NASDAQ:TVTX) is gaining on positive Phase 3 data for rare kidney disease treatments. The rare disease market, valued at $195 billion in 2024, is projected to grow at a 9.2% CAGR through 2030 (EvaluatePharma).

Immuneering (NASDAQ:IMRX) is driven by optimism for its oncology pipeline. The global oncology market, at $223 billion in 2025, is expected to reach $530 billion by 2032 (Grand View Research).

PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 247 is a third-party media provider and has been compensated by Microcap Advisory for providing ongoing LIXT market outreach and other services. Please review our Full Disclaimer https://www.247marketnews.com/disclaimer/. Please go to https://247marketnews.com/lixte-biotechnology/ for further LIXT and 247marketnews.com disclosure information.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (LIXT, CUPR, WLDS, ASST, AEHL, IMRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.